The World Health Organization released updated global guidelines on Wednesday stating that up to 45 per cent of dementia cases could be prevented or delayed by targeting modifiable risk factors, including tobacco use, harmful alcohol consumption, physical inactivity, air pollution, social isolation, and noncommunicable diseases such as hypertension and diabetes. The same week, a randomised clinical trial across 11 Latin American countries, published in The Lancet, reported that a structured multidomain lifestyle intervention produced cognitive improvements 55 per cent greater than those seen with standard health advice in older adults at elevated risk.

Both developments shift the prevention calculus from isolated recommendations to combined, sustained action. The LatAm-FINGERS trial, which followed 1,065 participants aged 60 to 77 over two years, bundled physical exercise, a culturally adapted healthy diet, cognitive training, cardiovascular risk control, and social engagement into a single protocol. Researchers in Medellín and Sabaneta, Colombia, who contributed 100 participants, noted that the programme was designed to test whether such a model could work in a region with wide socioeconomic diversity. A separate Swedish cohort study of over 27,000 adults, published in Alzheimer’s & Dementia, offers a mechanistic clue: each additional component of metabolic syndrome—abdominal obesity, elevated blood pressure, high blood sugar, high triglycerides, and low HDL cholesterol—was associated with a brain appearing up to 2.3 years older than chronological age, likely through chronic inflammation that damages cerebral blood vessels.

The WHO’s Geneva headquarters framed the guidelines as a translation of accumulated evidence into immediate policy options. For the first time, the agency explicitly recommends reducing exposure to air pollution and using hearing aids for those with hearing loss as dementia risk-reduction strategies, while advising against vitamin B, E, or omega-3 supplements absent a diagnosed deficiency. The economic stakes are substantial: dementia costs the global economy an estimated $1.3 trillion annually, roughly half of which represents unpaid care by families. Viewed from Latin American research centres, the trial’s significance lies in generating large-scale randomised evidence within the region rather than importing findings from high-income countries.

The LatAm-FINGERS results are scheduled for formal presentation at the Alzheimer’s Association International Conference in London, where attention will turn to how national health systems can integrate multidomain prevention into routine care for ageing populations.